Manufacturing: Page 2
-
Getty Images
Pharma reshoringPharma downplays tariff threat, even as risks remain unclear
Drugmaker executives have projected confidence they can mitigate the impact of any levies Trump imposes on the industry. Yet they're adjusting inventory and production nonetheless.
By Ned Pagliarulo , Jonathan Gardner • May 1, 2025 -
Chip Somodevilla via Getty Images
Merck takes $200M tariff hit, trimming its gross profits
The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial impact it’ll have for the rest of the year and beyond.
By Jonathan Gardner • April 24, 2025 -
Sedat Suna via Getty Images
Pharma reshoringRoche, answering tariff threat, pledges $50B to US drug production
The big pharma joined several of its peers in committing to invest billions of dollars in new and expanded manufacturing facilities in the U.S., among them a gene therapy plant in Pennsylvania.
By Jonathan Gardner • April 22, 2025 -
Getty Images
Trump administrationUS launches probe that could set stage for pharma tariffs
The Commerce Department has begun a so-called Section 232 investigation into the national security effects of the U.S. importing pharmaceuticals and their starting materials.
By Ned Pagliarulo • Updated April 14, 2025 -
Getty Images
Pharma reshoringAmid tariff turmoil, Novartis commits to spending $23B on US manufacturing
Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump administration buffets global trade with tariffs.
By Jonathan Gardner • April 10, 2025 -
Anna Moneymaker / Staff via Getty Images
Trump administrationTrump pauses most reciprocal tariffs, hikes China’s further
Drug company shares, which had sunk on comments by Trump that pharma duties would be coming soon, rallied along with the broader market.
By Philip Neuffer • April 9, 2025 -
Chip Somodevilla via Getty Images
Trump administrationMedtech industry pressures White House to exempt devices from tariffs
AdvaMed and other healthcare groups have pleaded for the Trump administration to exempt medical devices and critical supplies.
By Ricky Zipp • April 8, 2025 -
Getty Images
Tariffs send healthcare industry into ‘unchartered waters’
Provider groups and health systems warn tariffs will test healthcare’s fragile supply chain, threatening to create disruptions to patient care.
By Susanna Vogel • April 4, 2025 -
Andrew Harnik via Getty Images
Trump installs sweeping new tariffs, but pharma dodges blow
The president will impose a baseline 10% tariff on all countries, as well as higher levies on certain nations. Pharmaceutical goods appear to be exempt, at least for now.
By Philip Neuffer • Updated April 3, 2025 -
Kevin Dietsch via Getty Images
Pharma reshoringJ&J boosts US manufacturing as big pharma reshores
Following big announcements from Lilly and Merck, J&J is pledging $55 billion over the next four years to open new plants.
By Jonathan Gardner • March 21, 2025 -
Permission granted by Qiagen
Sponsored by QIAGEN Digital InsightsNGS is changing GxP compliance. Will you adapt?
Discover NGS for GxP compliance with full audit trails, operational control and robust data security.
By QIAGEN Digital insights • March 17, 2025 -
Courtesy of CordenPharma
Viking inks CordenPharma deal to boost obesity drug supply
The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched weight loss treatment.
By Jonathan Gardner • March 11, 2025 -
Courtesy of Merck Manufacturing Division Durham, North Carolina, HPV facility ribbon cutting
Merck opens $1B vaccine plant in North Carolina
Unveiling of the new factory comes as Merck and other pharma companies face pressure to reshore manufacturing back to the U.S.
By Delilah Alvarado • March 11, 2025 -
Permission granted by Syngene
Sponsored by SyngeneSynWeave™: Revolutionizing biopharma manufacturing by improving titer, timelines and manufacturability
Enhancing manufacturability is crucial for reducing the risks associated with scaling production.
March 10, 2025 -
Ned Pagliarulo/BioPharma Dive
Pharma reshoringLilly CEO wields manufacturing plans to push pharma-friendly policies
While announcing billions of dollars in new U.S. investments, David Ricks called for an extension of 2017 tax cuts and changes to Medicare's drug negotiation program.
By Ned Pagliarulo • Feb. 26, 2025 -
Scott Olson via Getty Images
Pharma reshoringLilly expands US manufacturing build-out with $50B target
The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry to reshore drug production.
By Ned Pagliarulo • Feb. 26, 2025 -
Justin Sullivan via Getty Images
How Trump’s trade fight could impact the medical device industry
Relocating manufacturing would require substantial capital investment, but the timespan for the president’s new tariffs is unclear, supply chain experts said.
By Susan Kelly • Feb. 12, 2025 -
Getty Images
Tariffs raise concern among generic drugmakers, as advocacy groups seek exemptions
“There is not a single member of AAM who has not raised concerns about the tariff situation,” said the CEO of the generic drug lobby Association for Accessible Medicines.
By Kelly Bilodeau • Feb. 7, 2025 -
Sarah Silbiger via Getty Images
Zepbound, Mounjaro shortages are resolved, FDA confirms
The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a limited grace period before taking any enforcement actions.
By Ned Pagliarulo • Dec. 19, 2024 -
Getty Images
Novo Holdings’ purchase of Catalent set to close after regulators’ green light
The $16.5 billion take-private deal can now be completed, along with Novo Nordisk’s related acquisition of three Catalent drug manufacturing plants.
By Ned Pagliarulo • Dec. 16, 2024 -
Scott Olson via Getty Images
Lilly adds to obesity drug production push with $3B investment
The expansion of a newly acquired facility in Wisconsin is Lilly’s largest U.S. manufacturing investment outside of Indiana and will help make more injectable drugs like fast-selling Zepbound.
By Jonathan Gardner • Dec. 6, 2024 -
Chip Somodevilla via Getty Images
What might a Trump administration mean for the Biosecure Act?
Analysts see Trump’s victory raising the high-profile legislation’s chances of becoming law. But the realities of a lame duck Congress may cause its timeline for passage to slip back.
By Amy Baxter • Nov. 20, 2024 -
Scott Olson via Getty Images
Novo sees Wegovy sales rise as supply constraints ease
Third quarter sales of Novo’s in-demand obesity drug totaled $2.5 billion, roughly 81% higher than the same period in 2023 and nearly doubling the total for Lilly’s Zepbound.
By Jonathan Gardner • Nov. 6, 2024 -
Getty Images
Novo takes big step toward ending Ozempic, Wegovy shortages
All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned patients may still experience "variability" filling their prescriptions.
By Ned Pagliarulo • Updated Oct. 30, 2024 -
Permission granted by MilliporeSigma
Sponsored by MilliporeSigmaAn effective analytical testing strategy for viral vectors should include these 7 steps
Producing safe, effective, high-quality viral vector therapeutics depends on a robust and tailored analytical testing strategy.
Oct. 7, 2024
Previous
